Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Imugene Limited
Eli Lilly and Company
Coherus Oncology, Inc.
ViroMissile, Inc.
Pfizer
Astellas Pharma Inc
Pfizer
Tizona Therapeutics, Inc
ALX Oncology Inc.
Genentech, Inc.
Eli Lilly and Company
Angiex, Inc.
NiKang Therapeutics, Inc.
Novartis
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics
General Oncology, Inc.
Kyowa Kirin Co., Ltd.
Zhejiang University
Eli Lilly and Company
National Cancer Institute (NCI)
IDEAYA Biosciences
MOMA Therapeutics
Plexium, Inc.
Massachusetts General Hospital
Novartis
City of Hope Medical Center
MOMA Therapeutics
GlaxoSmithKline
Sairopa B.V.
AccSalus Biosciences, Inc.
Abramson Cancer Center at Penn Medicine
Tyra Biosciences, Inc
National Cancer Institute (NCI)
IDRx Inc. - A GSK Company
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Incyte Corporation